|Bid||0.00 x 1200|
|Ask||0.00 x 800|
|Day's Range||35.75 - 37.68|
|52 Week Range||19.23 - 46.72|
|Beta (5Y Monthly)||1.26|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 22, 2023 - Feb 27, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||63.38|
Subscribe to Yahoo Finance Plus to view Fair Value for MORF
Waltham biotech Morphic Holding Inc. is no longer working with Johnson & Johnson Inc. after the pharma giant elected to terminate a nearly four-year-old collaboration agreement.
Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 2:15 PM PST. A live webcast of the presentation will be available on the Investor section of Morphic’s